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Materials and Methods. Bone marrow (BM) Lin
) and Lin Hematopoietic stem cells (HSCs) reside in fetal liver, cord blood, and adult bone marrow (BM) in very low frequencies, but perform a vital function of sustaining life-long production of all mature blood cells [1] [2] [3] [4] [5] . Various methods have been developed to enrich HSCs for functional studies as well as for clinical transplantation [6] [7] [8] [9] [10] . HSCs lack the expression of cell surface molecules for lineage-specific mature cells, and are, therefore, Lin À [6, 7, 10] . In mouse models, HSCs usually express stem cell antigen 1 (Sca1 þ ) and c-Kit (Kit þ , CD117), a transmembrane tyrosine kinase that serves as a receptor for stem cell factor [10] [11] [12] . These findings led to the establishment of Lin À Sca1 þ Kit þ (LSK) as a standard marker set for HSCs, although other antigens, such as CD34 and CD38, are often added to refine HSCs into even smaller populations [7, 9, 10] . The recent discovery of CD150 as a positive selection marker for HSCs provided a new strategy for HSC enrichment [4] . CD150 and two other members of the signaling lymphocyte activation molecule (SLAM) family proteins, CD48 and CD244, have stage-specific expression patterns on hematopoietic cells [4] . CD150-positive selection has been successfully applied to enrich HSCs from mouse fetal liver and from BM of old and young mice [4, 13, 14] . A recent study using the combination of CD150 selection, Hoechst dye efflux side population and canonical markers for HSC enrichment has confirmed the potential of CD150-positive selection for HSC enrichment, but found that HSC activity is also present in the CD150
À cells fraction [15] .
In the current study, we tested HSC function in normal C57BL/6J (B6) and B6.129S2-Trp53 tm1Tji /J (Trp53 null) mice using enriched HSC populations based on the SLAM and LSK markers. We specifically selected the Trp53 null mice for the study because Trp53 is a cell-cycle regulator that affects HSC function. It was found that Trp53 null mice have a greater number of HSCs responsible for reconstitution of lethally irradiated recipients after 5-fluorouracil treatment [16] . It was also observed that Trp53 null mice have a larger pool of LSK cells in the BM, and that whole BM (WBM) cells from Trp53 null donors had higher competitive repopulating ability relative to wild-type B6 donor cells, but 56% of recipients of Trp53 null BM cells died within 5 months following cell infusion [17] . These findings implied that overall HSC function is upregulated in the BM of Trp53 null mice with undefined cause of early recipient death.
We conducted this study aimed to verify CD150 as a positive selection marker for HSC enrichment and to understand whether HSCs from Trp53 null mice are truly functionally advantageous when enriched cells in addition to WBM cells are used for the engraftment assay. By using fluorescence-activated cell sorting (FACS), competitive repopulation (CR), and serial transplantation assays, we demonstrated that BM cells defined by the SLAM and LSK markers were both highly enriched for HSC activity in B6 and Trp53 null mice. Upon retransplantation, SLAMenriched B6 HSCs maintained high functional ability in the secondary recipients. Using SLAM and LSK cells in the CR assay, we found that HSC engraftment ability was lower in cells from Trp53 null than from normal B6 mice, which differed from the outcome when WBM cells were used as the HSC source. Our findings support the usage of CD150 as a positive selection marker for HSC enrichment, and provide fresh evidence indicating that Trp53 deficiency may upregulate HSC self-renewal, but does not produce a true functional advantage for engraftment.
Materials and methods
Mice Inbred B6, congenic B6.SJL-Ptprc (B6-CD45.1), and Trp53 null mice were originally obtained from the Jackson Laboratory (Bar Harbor, ME, USA), and were bred and maintained in the National Institutes of Health animal facility. All mice were used at 2 to 4 months of age. The B6-CD45.1 and Trp53 null mice had been backcrossed to B6 for 22 and 12 generations, respectively, to ensure a relatively pure B6 genetic background [18] . Animal studies were approved by the National Heart, Lung, and Blood Institute Animal Care and Use Committee.
Flow cytometry cell staining and cell sorting BM cells were flushed from tibiae and femurs of both legs of each donor or competitor mouse into 2 mL Iscove's modified Dulbecco's media, filtered through a 90-mm nylon mesh, and counted by a ViCell counter (Beckman Coulter, Miami, FL, USA) before use. Monoclonal antibodies for mouse CD3 (clone 145-2C11), CD4 (clone GK 1.5), CD8 (clone 53-6.72), CD11b (clone M1/70), CD41 (clone MWReg 30), CD45R (B220, clone RA3-6B2), CD48 (Clone BCM1) CD117 (c-Kit, clone 2B8), erythroid cells (clone Ter119), granulocytes (Gr1/Ly6-G, clone RB6-8C5), and stem cell antigen 1 (Sca1, clone E13-161), were from BD Biosciences (San Diego, CA, USA). Antibodies were conjugated to fluorescein isothiocyanate (FITC), phycoerythrin (PE), or allophycocyanin (APC). Anti-mouse CD150 antibody was from Biolegend (San Diego, CA, USA) while the fluorescent probe 2 0 ,7 0 -dichlorofluorescein diacetate (DCF-DA) dye was from Invitrogen (Carlsbad, CA, USA).
Procedures for flow cytometry were adapted as described previously [17] . 3 , and 1% bovine serum albumin), cells were incubated with antibody mixtures on ice for 30 minutes. We used the antibody mixture CD41-FITC þ CD48-FITC þ Lin-PE (CD3, CD4, CD8, CD11b, CD45R, Gr1, Ter119) þ CD150-APC for the staining of SLAM cells and the antibody mixture Lin-PE þ Sca1-PE-Cy7 þ CD117-APC for the staining of LSK cells. After each staining and washing step, cells were centrifuged at 500g for 5 minutes at 4 C. Acquisition was carried out using a BD-LSR II flow cytometer with the FACSDiva software (Becton Dickinson, San Jose, CA). The procedure used for reactive oxygen species (ROS) measurement was the same as described earlier [19] . BM cells were incubated with the DCF-DA dye and the anti-mouse CD150-APC antibody in a 37 C water bath for 30 minutes and then washed and acquired, as described here.
For cell sorting, BM cells from B6 and Trp53 null donors were stained with CD41-FITC þ CD48-FITC þ Lin-PE þ CD150-APC antibody mixture and were separated into Lin 6 competitor BM cells without donor cells were used as controls to monitor average host contribution, which was subtracted from the donor contribution at each time point. Two weeks after the 6-month measurement, the recipient from each donor cell group that had the highest donor cell contribution was euthanized, and BM cells were serially transplanted into a new set of lethally irradiated (11 Gy TBI) B6 recipients at 15 Â 10 6 cells per recipient, three recipients per donor. The proportions of CD45.2 donor and CD45.1 competitor cell engraftment in the secondary recipients were measured at 2, 6, 14, and 27 weeks using the same methods.
To further validate observations from engraftment using SLAM cells, we then sorted out LSK BM cells from B6 and Trp52 null donors and mixed them 1:300 with a pool of B6-CD45.1 competitor cells and then transplanted the cell mixture into lethally irradiated young B6 recipients in another CR assay. We used six recipients for each donor type. As a comparison, we also mixed unfractionated WBM cells from the same B6 and Trp53 null donors with competitor BM cells at 1:1 and transplanted the cell mixtures into recipients in the same assay. Donor contributions were measured at 4, 8, and 11 weeks after transplantation.
Data analyses
Data from cell proportion and competitive engraftment measurements were analyzed by the JMP statistical software (SAS Institute Inc., Cary, NC, USA) using single factor (genotype: B6 vs Trp53 null) and two-factor (genotype Â cell type) models [20] . Data are presented as means with standard errors. Statistical significance p values are given wherever a significant difference exists.
Results
Correlation between SLAM and LSK cell populations When BM cells from B6 and Trp53 null mice were stained for the Lin
þ SLAM markers, we found a cell population at frequencies of 0.0078% 6 0.0010% and 0.0135% 6 0.0010% of total BM cells for B6 and Trp53 null mice, respectively (Fig. 1A) . When we stained BM cells from the same mice with the well-established HSC-containing LSK markers, the LSK cell populations were found to be 0.0165% 6 0.0035% for B6 and 0.0276% 6 0.0035% for Trp53 mice, respectively (Fig. 1A) . Both the SLAM (p ! 0.0019) and the LSK cell (p ! 0.05) populations were significantly larger in Trp53 null than in B6 mice (Fig. 1B) . From these measurements, we found a significant correlation between SLAM and LSK cell proportions (R 2 5 0.7116; p ! 0.0013; Fig. 1C) , as well as a significant correlation between total SLAM and total LSK cells (R 2 5 0.7705; p ! 0.0005; Fig. 1C ), suggesting that SLAM cells, just as LSK cells, could be highly enriched for HSCs.
Lower level of ROS in CD150
þ cells To test whether the SLAM cell population actually enriched HSCs, we first analyzed the DCF-DA dye uptake in CD150 þ and CD150 À BM cells from B6 and Trp53 null mice as a measurement of cellular ROS content. The proportion of ROS low cells in total BM was similar between B6 and Trp53 null mice ( Fig. 2A) . However, CD150 þ BM cells from B6 and Trp53 null mice both had significantly higher proportions of (p ! 0.0001) ROS low cells (79.5% 6 1.68% and 83.6% 6 1.68%) CD150 À BM cells (71.1% 6 1.68% and 71.6% 6 1.68%, Fig. 2B and C) , suggesting that the CD150 þ cell fraction contains more cells that are primitive and inactive than the CD150 À cell fraction. 
Enrichment of functional HSCs in the SLAM cell population
Next we sorted and mixed SLAM and SLAM À cells from B6 and Trp53 donors with competitor BM cells and transplanted them into lethally irradiated recipients (Fig. 3A) . The SLAM À cell contribution was relatively high at the first 2 months (6% to 8%), but reduced gradually thereafter to 4% to 5% at 5 and 6 months. To the opposite, the SLAM cell contribution increased steadily over time from 4% to 6% at 1 month to 12% to 13% at 5 and 6 months (Fig. 3B) . The large gap in the donor-to-competitor cell ratio is probably responsible for the low overall donor contribution and high variability among the four recipients from each group, hampering the possibility to achieve statistical significance when the means of donor contributions were compared among the different donor cell types. To test whether there is a significant difference in HSC function between SLAM and SLAM À cells, we retransplanted BM cells from first round recipients into lethally irradiated secondary hosts. Indeed, SLAM cells showed significantly higher levels of donor contribution than SLAM À cells when engrafted into secondary hosts for 2 (44.3% 6 2.0% vs 13.4% 6 2.5%; p ! 0.0001), 6 (78.1% 6 2.3% vs 21.7% 6 2.8%; p ! 0.01), 14 (76.1% 6 2.8% vs 14.7% 6 3.4%; p ! 0.0001), and 27 (75.6 6 3.7 vs 17.2 6 4.5; p ! 0.0001) weeks, showing that SLAM cells are much better enriched for HSCs than SLAM À cells (Fig. 4A and B) .
Reduced engraftment from Trp53 null SLAM cells
In comparison to SLAM cells from normal B6 donors (12-13%), Trp53 null SLAM cells (7.5-8.5%) had much lower contribution to recipient engraftment, suggesting a possible HSC functional decline in Trp53 null mice (Fig. 3B) . Upon serial transplantation, Trp53 null SLAM cell contributions were 34.9% 6 2.4%, 29.8% 6 2.3%, 20.8% 6 2.8%; 21.9% 6 3.7% at 2, 6, 14, and 27 weeks, respectively, much lower (p ! 0.01) than the 44.3% 6 2.0%, 78.1% 6 2.3%, 76.1% 6 2.8%, and 75.6 6 3.7 donor contribution from B6 SLAM cells. It seems that the difference in repopulating ability between Trp53 null and B6 SLAM cells enlarged over time in the secondary hosts (Fig. 4B) . In this study, all recipients survived and examination of three recipients of B6 SLAM cells and three recipients of Trp53 null SLAM cells at 13 months following initial transplantation found no gross pathologic change or obvious tumor formation. Blood smear revealed normal cell morphology and distribution with no sign of leukemia. All secondary recipients also survived without obvious abnormality except having lower levels (p ! 0.05) of circulating WBCs, neutrophils, and lymphocytes in comparison to secondary recipients of B6 SLAM cells (Table 1) .
Lower HSC function in Trp53 null LSK cells
To test whether the reduced engraftment from Trp53 null SLAM cells truly represent a lower HSC function in Trp53 null mice, we next sorted LSK cells from the BM of Trp53 null and B6 mice and engrafted cells into lethally irradiated B6 recipients in another CR assay. Contributions from Trp53 null and B6 LSK cells were 22.7% 6 3.4% and 24.0% 6 3.1% at 4 weeks, 13.5% 6 4.9%, and 19.0% 6 4.5% at 8 weeks, and 20.9% 6 3.7%, and 33.8% 6 3.1% (p ! 0.05) at 11 weeks after transplantation (Fig. 5) . We also mixed WBM cells from the same Trp53 null and B6 donors 1:1 with WBM cells from the same B6-CD45.1 competitors in the same CR assay, and found that Trp53 null WBM cells engrafted equally well or better than B6 WBM cells with donor contributions of 38.2% 6 1.2% and 42.0% 6 1.2% at 4 weeks, 50.4% 6 3.4% and 47.3% 6 2.4% at 8 weeks, and 74.1% 6 2.7% and 69.2% 6 1.9% at 11 weeks (Fig. 5) . Two of the four recipients of Trp53 null WBM cells died between 8 and 11 weeks while all other recipients survived. We were not able to determine the cause of death for these two recipients. For the remaining recipients, complete blood counts showed no difference among the four donor cell types (data not shown, similar to those in Table 1 ). Results from this study indicate that Trp53 null LSK cells are also less functional for engraftment than B6 LSK cells while overall HSC number is still higher in the BM of Trp53 null than in normal B6 mice.
Discussion
Characterization of CD150 as a HSC marker added a new method for HSC enrichment [4, 13, 14] . In the current study, we combined CD150 selection with the conventional Lin À marker set along with negative selection for CD41 and CD48 to isolate Lin inactive and contain lower levels of ROS. Our results are in agreement with a recent report by Jang et al. [21] , in which primitive HSCs had lower levels of ROS whereas ROS hi cells display signs of HSC exhaustion through serial transplantation. In a mouse model of Fanconi anemia, administration of the proinflammatory cytokine tumor necrosis factor a-induced premature senescence in BM HSCs, progenitor cells with higher Trp53, higher level of ROS, and more oxidative DNA damage [22] . The fact that SLAM cells are highly enriched for HSCs by CR and serial transplantation assessments provided definitive evidence showing that CD150-based SLAM markers are a useful set of markers effective for the enrichment of long-term functional HSCs, consistent with the original report showing much higher HSC activity in CD150 þ BM cells [4] . We did observe HSC activity in the SLAM À cell fraction through CR and serial transplantation, indicating that not all HSCs are in the CD150 þ cell population. This result is in agreement with a recent report showing that CD150 À cells are present in the Hoechst dye efflux side population with HSC activity [15] .
A major finding from this study is the lower HSC functional ability in SLAM cells from Trp53 null mice in comparison to those from normal B6 mice through CR and serial transplantation. This observation is further confirmed by a separate study in which LSK cells from Trp53 null donors also had lower engraftment ability than LSK cells from normal B6 donors. These results seemed to differ from early studies showing a general elevation in HSC number and activity in Trp53 null mice [16, 17, 23] . However, when WBM cells from the same donors were used for the assay, we indeed found that HSC activity is elevated in Trp53 null mice, consistent with previous studies [16, 17, 23] . All recipients of Trp53 null SLAM, SLAM À , and LSK cells and B6 SLAM, SLAM À , LSK, and WBM cells survived through CR and/or serial transplantation with no signs of leukemia or tumor development. However, two recipients of Trp53 null WBM cells died between 8 and 11 weeks. In a previous study, 56% of recipients of Trp53 null WBM cells died within 5 months after cell transplantation [17] . One possibility regarding recipient death is a potential ''adverse'' effect produced by all Trp53 null cells. In such a case, the relatively lower level of engraftment from Trp53 null SLAM and LSK cells might have limited the adverse effect and, therefore, prevented recipient mortality. Another possible explanation is the presence of ''adverse'' cells in the WBM, but not SLAM or LSK cells, in Trp53 null mice. These ''adverse'' cells might only proliferate Data shown as mean 6 standard error of mean from a two-way variance analysis with interactions using three recipients per group. S and s: significant strain difference at p ! 0.01 or p ! 0.05, respectively. NS 5 no significance; RBC 5 red blood cell; WBC 5 white blood cell. when transplanted into lethally irradiated recipients in an active cytokine environment. We could not distinguish these two possibilities because the exact cause of recipient mortality remains unknown. The fact that SLAM and LSK cells from Trp53 null donors had lower engraftment ability than normal B6 SLAM and LSK cells can at least be partially explained by a cell number effect. Both the LSK and SLAM cell populations were larger in Trp53 null than in normal B6 mice, consistent with findings from previous reports showing elevated HSC presence in Trp53 null mice [16, 17, 23, 24] . This finding is also in line with findings from p21-deficient mice in which HSC proliferation and absolute numbers increased while HSC functionality in serial transplantation decreased in p21-deficient mice [25, 26] . Together, results from this study indicate that HSC self-renewal, but not functional ability per cell, is elevated in mice deficient for Trp53.
